ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
16 Aug 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Sunesis Pharmaceuticals to Present at Lehman Brothers Ninth Annual Global Healthcare Conference

08/03/2006 1:30pm

PR Newswire (US)


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Sunesis Pharmaceuticals Charts.
SOUTH SAN FRANCISCO, Calif., March 8 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Daniel N. Swisher, Jr., President and Chief Executive Officer, will present a company update at the Lehman Brothers Ninth Annual Global Healthcare Conference in South Beach, FL on March 10, 2006 at 11:15 a.m. local time. Interested parties may access the webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com/ . A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until March 24, 2006. About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com/ . Forward-Looking Statements This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals, Inc. Web site: http://ir.sunesis.com/ Web site: http://www.sunesis.com/

Copyright

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock